The EIF4EBP3 translational repressor is a marker of CDC73 tumor suppressor haploinsufficiency in a parathyroid cancer syndrome

Cell Death and Disease

Volumn 3, Issue 2, 2012, Pages

  Zhang, J H ^a   Seigneur, E M ^a   Pandey, M ^a   Loshakov, A ^a   Dagur, P K ^b   Connelly, P S ^c   Koo, L ^b   Panicker, L M ^a,d   Simonds, W F ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^d UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

4E BP; Apoptosis; eIF4E; HRPT2; PAF1 complex; s6k

Indexed keywords

CDC73 PROTEIN; EUKARYOTIC TRANSLATION INITIATION FACTOR 4E BINDING PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; REPRESSOR PROTEIN; TUMOR MARKER; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; CARBOXYLYASE; CARRIER PROTEIN; CDC73 PROTEIN, HUMAN; DROSOPHILA PROTEIN; EIF4EBP3 PROTEIN, HUMAN; MEN1 PROTEIN, HUMAN; MNN1 PROTEIN, DROSOPHILA; ONCOPROTEIN; PARAFIBROMIN PROTEIN, DROSOPHILA; PROTEIN TYROSINE KINASE; TARGET OF RAPAMYCIN KINASE; TORSO PROTEIN, DROSOPHILA;

ALLELE; ARTICLE; BENIGN TUMOR; CANCER SUSCEPTIBILITY; CELL STRAIN HEK293; CHROMATIN IMMUNOPRECIPITATION; DROSOPHILA; GENE EXPRESSION PROFILING; GENE INACTIVATION; GENE INTERACTION; GENE MUTATION; GENETIC SUSCEPTIBILITY; HAPLOINSUFFICIENCY; HETEROZYGOSITY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HYRAX; IMMUNOBLOTTING; MALIGNANT TRANSFORMATION; MULTIPLE ENDOCRINE NEOPLASIA; NONHUMAN; PARATHYROID CARCINOMA; PHENOTYPE; PRIORITY JOURNAL; SEQUENCE HOMOLOGY; TUMOR SUPPRESSOR GENE; ANIMAL; AUTOPHAGY; DROSOPHILA MELANOGASTER; GENETICS; HETEROZYGOTE; METABOLISM; MUTATION; PARATHYROID GLAND; PARATHYROID TUMOR; PATHOLOGY; PROTEIN SYNTHESIS; SIGNAL TRANSDUCTION; SYNDROME;

EUKARYOTA; MAMMALIA; PROCAVIIDAE;

ANIMALS; AUTOPHAGY; BIOLOGICAL MARKERS; CARBOXY-LYASES; CARRIER PROTEINS; DROSOPHILA MELANOGASTER; DROSOPHILA PROTEINS; GERM-LINE MUTATION; HAPLOINSUFFICIENCY; HETEROZYGOTE; HUMANS; PARATHYROID GLANDS; PARATHYROID NEOPLASMS; PROTEIN BIOSYNTHESIS; PROTO-ONCOGENE PROTEINS; RECEPTOR PROTEIN-TYROSINE KINASES; SEQUENCE HOMOLOGY, AMINO ACID; SIGNAL TRANSDUCTION; SYNDROME; TOR SERINE-THREONINE KINASES; TUMOR SUPPRESSOR PROTEINS;

EID: 84863247529     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2012.6     Document Type: Article

References (40)

1. Jackson CE, Norum RA, Boyd SB, Talpos GB, Wilson SD, Taggart RT et al. Hereditary hyperparathyroidism and multiple ossifying jaw fibromas: a clinically and genetically distinct syndrome. Surgery 1990; 108: 1006-1012.
2. Mallette LE, Malini S, Rappaport MP, Kirkland JL. Familial cystic parathyroid adenomatosis. Ann Intern Med 1987; 107: 54-60. (Pubitemid 17098638)
3. Teh BT, Farnebo F, Kristoffersson U, Sundelin B, Cardinal J, Axelson R et al. Autosomal dominant primary hyperparathyroidism and jaw tumor syndrome associated with renal hamartomas and cystic kidney disease: linkage to 1q21-q32 and loss of the wild type allele in renal hamartomas. J Clin Endocrinol Metab 1996; 81: 4204-4211. (Pubitemid 26412018)
4. Teh BT, Farnebo F, Twigg S, Höög A, Kytölä S, Korpi-Hyövälti E et al. Familial isolated hyperparathyroidism maps to the hyperparathyroidism-jaw tumor locus in 1q21-q32 in a subset of families. J Clin Endocrinol Metab 1998; 83: 2114-2120. (Pubitemid 28496346)
5. Simonds WF, James-Newton LA, Agarwal SK, Yang B, Skarulis MC, Hendy GN et al. Familial isolated hyperparathyroidism: Clinical and genetic characteristics of thirty-six kindreds. Medicine (Baltimore) 2002; 81: 1-26. (Pubitemid 34081284)
6. Simonds WF, Robbins CM, Agarwal SK, Hendy GN, Carpten JD, Marx SJ. Familial isolated hyperparathyroidism is rarely caused by germline mutation in HRPT2, the gene for the hyperparathyroidism-jaw tumor syndrome. J Clin Endocrinol Metab 2004; 89: 96-102. (Pubitemid 38183866)
7. Carpten JD, Robbins CM, Villablanca A, Forsberg L, Presciuttini S, Bailey-Wilson J et al. HRPT2, encoding parafibromin, is mutated in hyperparathyroidism-jaw tumor syndrome. Nat Genet 2002; 32: 676-680. (Pubitemid 35435184)
8. Shattuck TM, Valimaki S, Obara T, Gaz RD, Clark OH, Shoback D et al. Somatic and germ-line mutations of the HRPT2 gene in sporadic parathyroid carcinoma. N Engl J Med 2003; 349: 1722-1729. (Pubitemid 37315009)
9. Cetani F, Pardi E, Borsari S, Viacava P, Dipollina G, Cianferotti L et al. Genetic analyses of the HRPT2 gene in primary hyperparathyroidism: germline and somatic mutations in familial and sporadic parathyroid tumors. J Clin Endocrinol Metab 2004; 89: 5583-5591. (Pubitemid 39518444)
10. Wade PA, Werel W, Fentzke RC, Thompson NE, Leykam JF, Burgess RR et al. A novel collection of accessory factors associated with yeast RNA polymerase II. Protein Expr Purif 1996; 8: 85-90. (Pubitemid 26326216)
11. Shi X, Chang M, Wolf AJ, Chang CH, Frazer-Abel AA, Wade PA et al. Cdc73p and Paf1p are found in a novel RNA polymerase II-containing complex distinct from the Srbp-containing holoenzyme. Mol Cell Biol 1997; 17: 1160-1169. (Pubitemid 27097345)
12. Rozenblatt-Rosen O, Hughes CM, Nannepaga SJ, Shanmugam KS, Copeland TD, Guszczynski T et al. The parafibromin tumor suppressor protein is part of a human Paf1 complex. Mol Cell Biol 2005; 25: 612-620. (Pubitemid 40096583)
13. Yart A, Gstaiger M, Wirbelauer C, Pecnik M, Anastasiou D, Hess D et al. The HRPT2 tumor suppressor gene product parafibromin associates with human PAF1 and RNA polymerase II. Mol Cell Biol 2005; 25: 5052-5060. (Pubitemid 40781105)
14. Zhu B, Mandal SS, Pham AD, Zheng Y, Erdjument-Bromage H, Batra SK et al. The human PAF complex coordinates transcription with events downstream of RNA synthesis. Genes Dev 2005; 19: 1668-1673. (Pubitemid 41058361)
15. Mosimann C, Hausmann G, Basler K. Parafibromin/Hyrax activates Wnt/Wg target gene transcription by direct association with beta-catenin/Armadillo. Cell 2006; 125: 327-341. (Pubitemid 44313810)
16. Krebs LJ, Shattuck TM, Arnold A. HRPT2 mutational analysis of typical sporadic parathyroid adenomas. J Clin Endocrinol Metab 2005; 90: 5015-5017. (Pubitemid 41262247)
17. Bradley KJ, Cavaco BM, Bowl MR, Harding B, Cranston T, Fratter C et al. Parafibromin mutations in hereditary hyperparathyroidism syndromes and parathyroid tumours. Clin Endocrinol 2006; 64: 299-306.
18. Gagel RF, Marx SJ. Multiple endocrine neoplasia. In: Kronenberg HM, Melmed S, Polonsky KS, Larsen PR (eds) Williams Textbook of Endocrinology 11th edn. WB Saunders & Co: Philadelphia, 2007, pp 1705-1746.
19. Heppner C, Kester MB, Agarwal SK, Debelenko LV, Emmert-Buck MR, Guru SC et al. Somatic mutation of the MEN1 gene in parathyroid tumours. Nat Genet 1997; 16: 375-378. (Pubitemid 27323304)
20. Farnebo F, Teh BT, Kytola S, Svensson A, Phelan C, Sandelin K et al. Alterations of the MEN1 gene in sporadic parathyroid tumors. J Clin Endocrinol Metab 1998; 83: 2627-2630. (Pubitemid 28493751)
21. Wang P, Bowl MR, Bender S, Peng J, Farber L, Chen J et al. Parafibromin, a component of the human PAF complex, regulates growth factors and is required for embryonic development and survival in adult mice. Mol Cell Biol 2008; 28: 2930-2940. (Pubitemid 351556526)
22. Lin L, Zhang JH, Panicker LM, Simonds WF. The parafibromin tumor suppressor protein inhibits cell proliferation by repression of the c-myc proto-oncogene. Proc Natl Acad Sci USA 2008; 105: 17420-17425.
23. Rozenblatt-Rosen O, Nagaike T, Francis JM, Kaneko S, Glatt KA, Hughes CM et al. The tumor suppressor Cdc73 functionally associates with CPSF and CstF 3 mRNA processing factors. Proc Natl Acad Sci USA 2009; 106: 755-760.
24. Zhang JH, Panicker LM, Seigneur EM, Lin L, House CD, Morgan W et al. Cytoplasmic polyadenylation element binding protein is a conserved target of tumor suppressor HRPT2/CDC73. Cell Death Differ 2010; 17: 1551-1565.
25. Sancak Y, Thoreen CC, Peterson TR, Lindquist RA, Kang SA, Spooner E et al. PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase. Mol Cell 2007; 25: 903-915. (Pubitemid 46436534)
26. Sengupta S, Peterson TR, Sabatini DM. Regulation of the mTOR complex 1 pathway by nutrients, growth factors, and stress. Mol Cell 2010; 40: 310-322.
27. Robert F, Pelletier J. Translation initiation: a critical signalling node in cancer. Expert Opin Ther Targets 2009; 13: 1279-1293.
28. Mamane Y, Petroulakis E, LeBacquer O, Sonenberg N. mTOR, translation initiation and cancer. Oncogene 2006; 25: 6416-6422. (Pubitemid 44582285)
29. Graff JR, Zimmer SG. Translational control and metastatic progression: enhanced activity of the mRNA cap-binding protein eIF-4E selectively enhances translation of metastasis-related mRNAs. Clin Exp Metastasis 2003; 20: 265-273. (Pubitemid 36513230)
30. Yeh CJ, Chuang WY, Chao YK, Liu YH, Chang YS, Kuo SY et al. High expression of phosphorylated 4E-binding protein 1 is an adverse prognostic factor in esophageal squamous cell carcinoma. Virchows Arch 2011; 458: 171-178.
31. Li BD, Liu L, Dawson M, De Benedetti A. Overexpression of eukaryotic initiation factor 4E (eIF4E) in breast carcinoma. Cancer 1997; 79: 2385-2390. (Pubitemid 27251022)
32. Rojo F, Najera L, Lirola J, Jimenez J, Guzman M, Sabadell MD et al. 4E-binding protein 1, a cell signaling hallmark in breast cancer that correlates with pathologic grade and prognosis. Clin Cancer Res 2007; 13: 81-89. (Pubitemid 46121856)
33. Castellvi J, Garcia A, Rojo F, Ruiz-Marcellan C, Gil A, Baselga J et al. Phosphorylated 4E binding protein 1: a hallmark of cell signaling that correlates with survival in ovarian cancer. Cancer 2006; 107: 1801-1811. (Pubitemid 44582949)
34. Wolff T, Ready DF. Cell death in normal and rough eye mutants of Drosophila. Development 1991; 113: 825-839. (Pubitemid 21900322)
35. Lasko P. Gene regulation at the RNA layer: RNA binding proteins in intercellular signaling networks. Sci STKE 2003; 2003: RE6.
36. Miron M, Lasko P, Sonenberg N. Signaling from Akt to FRAP/TOR targets both 4E-BP and S6 K in Drosophila melanogaster. Mol Cell Biol 2003; 23: 9117-9126. (Pubitemid 37499801)
37. Zoncu R, Efeyan A, Sabatini DM. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol 2011; 12: 21-35.
38. Mueller CL, Jaehning JA. Ctr9, Rtf1, and Leo1 are components of the Paf1/RNA polymerase II complex. Mol Cell Biol 2002; 22: 1971-1980. (Pubitemid 34224606)
39. Haven CJ, Howell VM, Eilers PH, Dunne R, Takahashi M, van Puijenbroek M et al. Gene expression of parathyroid tumors: molecular subclassification and identification of the potential malignant phenotype. Cancer Res 2004; 64: 7405-7411. (Pubitemid 39372081)
40. Lin L, Czapiga M, Nini L, Zhang JH, Simonds WF. Nuclear localization of the parafibromin tumor suppressor protein implicated in the hyperparathyroidism- jaw tumor syndrome enhances its proapoptotic function. Mol Cancer Res 2007; 5: 183-193. (Pubitemid 46423999)